Special Issue

HOX Genes in Cancer

Message from the Guest Editors

The HOX genes are a family of transcription factors that play key roles in conferring cell and tissue identity during early development, but which are also frequently expressed at very high levels in a wide range of solid and hematological cancers. Over the last decade is has become apparent that the HOX genes can promote oncogenesis and the maintenance of a malignant phenotype, and are therefore potential therapeutic targets in cancer as well as biomarkers for diagnosis, prognosis, and patient stratification. This Special Issue, *HOX Genes in Cancer*, will provide a forum for the latest discoveries in this rapidly expanding field, and help make it accessible through reviews on key topics including the role of HOX genes in cancer stem cells, current progress on targeting HOX proteins in cancer, the cancer-specific functions of HOX genes, and the potential of HOX genes and their products as biomarkers.

Dr. Alex Thompson

Guest Editors

Prof. Dr. Richard Morgan

Institute of Cancer Therapeutics, University of Bradford, Bradford, West Yorkshire BD7 1DP, UK

Prof. Dr. Keith D. Hunter

Unit of Oral and Maxillofacial Pathology, School of Clinical Dentistry, University of Sheffield, Sheffield, UK

Dr. Alex Thompson

School of Medicine, University of Nottingham, Nottingham, UK

Deadline for manuscript submissions

closed (31 March 2019)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/19016

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)